{
    "nct_id": "NCT05388877",
    "official_title": "Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases from BRAF V600-Mutated Metastatic Melanoma",
    "inclusion_criteria": "* Age >= 18 years\n* Histologically or cytologically confirmed stage IV metastatic BRAF V600-mutated melanoma\n* Documented metastasis of the primary tumor to the CNS\n* BRAF-mutation melanoma tumor status will be established prior to entry based on previous BRAF-gene analysis reports from a Clinical Laboratory Improvement Act (CLIA) qualified laboratory. If a report is not available, the mutation analysis will be performed at screening on archival tissue\n* At least one brain metastasis, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) with contrast =< 3 weeks prior to registration and does not require immediate local intervention (surgery or radiosurgery)\n* Asymptomatic or symptomatic CNS metastasis\n* Systemic, measurable metastatic melanoma disease is allowed; leptomeningeal disease is allowed.\n* Prior stereotactic radiosurgery and/or excision of brain metastases is allowed > 3 weeks before initiation of study treatment\n* Prior immunotherapy for adjuvant or metastatic disease is allowed provided there is documented progression of disease following treatment\n* Prior melanoma adjuvant BRAF/MEK inhibitor treatment is allowed if >= 12 months has elapsed between the end of therapy and initiation of study treatment\n* Able to swallow and retain oral medication with no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels\n* Stable dose of corticosteroids for CNS metastasis is allowed if >= 7 days\n* Seizures due to CNS metastases must be controlled with stable anti-epileptic treatment for >= 14 days\n* Bisphosphonates and/or denosumab are allowed\n* Life expectancy >= 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* Hemoglobin (Hb) >= 9 g/dL without ongoing transfusional support (obtained =< 15 days prior to registration)\n* Absolute neutrophil count (ANC) >= 1.0 x 10^9 cells/L without ongoing transfusional support (obtained =< 15 days prior to registration)\n* Platelets >= 75 x 10^9 cells/L without ongoing transfusional support (obtained =< 15 days prior to registration)\n* Creatinine =< 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance >= 50 mL/minute per the Cockcroft-Gault formula (obtained =< 15 days prior to registration)\n* Total bilirubin =< 2 times the upper limit of normal (ULN) unless due to Gilbert's disease (obtained =< 15 days prior to registration)\n* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times ULN, or < 5 times ULN for subjects with liver metastases (obtained =< 15 days prior to registration)\n* Negative serum pregnancy test done =< 14 days prior to registration, for persons of childbearing potential only, defined as a female who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months)\n* Willing to use contraception\n* Sexually active persons of childbearing potential (PCBP) and persons able to father a child must agree to use adequate methods to avoid pregnancy throughout the study and for 28 days after the completion of study treatment\n* Provide written informed consent\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n* Ability to complete Patient Medication Diaries by themselves or with assistance\n* Willingness to have institution procure previous BRAF-gene analysis report(s) from a CLIA qualified laboratory, or if a report is not available, willingness to have institution procure archived tumor sample to establish BRAF-mutational melanoma tumor status prior to study\n* Ability to swallow\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Urgent need of treatment to prevent acute neurologic deterioration, including urgent neurosurgery or radiotherapy\n* Symptoms of uncontrolled intracranial pressure\n* Symptomatic or untreated spinal cord compression\n* Serious cardiac condition =< 6 months prior to registration, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) class III or class IV\n* Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment\n* Uncontrolled intercurrent non-cardiac illness including, but not limited to:\n\n  * Ongoing or active infection requiring IV antibiotic usage within the last week prior to study treatment\n  * Any other conditions that would limit compliance with study requirements or confound the interpretation of study results\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Any of the following, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception",
    "miscellaneous_criteria": ""
}